Phillip Terry Meikle II - 28 Sep 2026 Form 4 Insider Report for Bone Biologics Corp (BBLG)

Reporting relationship: Director
Issuer ticker: BBLG
Reported as of: 28 Sep 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 30 Sep 2026, 17:09:07 UTC
Prior SEC filing: 06 Jun 2025
Source filing: View source filing
Reporting owner signature: /s/ Phillip Meikle

Key filing fact

Phillip Terry Meikle II filed Form 4 for Bone Biologics Corp (BBLG) on 30 Sep 2026.

Key facts

This page summarizes Phillip Terry Meikle II's Form 4 filing for Bone Biologics Corp (BBLG).
1 reported transaction and 4 derivative rows are listed below.
Accepted by SEC: 30 Sep 2026, 17:09.

Change

Previous filing in this sequence was filed on 06 Jun 2025.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0002041874 Primary reporting owner

Meikle Phillip Terry II

Relationship: Director
Address: C/O BONE BIOLOGICS CORP, 2 BURLINGTON WOODS DR. SUITE 100, BURLINGTON
Signature: /s/ Phillip Meikle
Signature date: 30 Sep 2026

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

BBLG transaction Derivative

Non-Employee Stock Option

Award

Transaction value
Shares: +113,896
Change %
Price: $0.000000^*
Shares after: 113,896
Date: 28 Sep 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 113,896
Exercise price: $0.5000
Footnotes: F1

BBLG holding Derivative

Non-Employee Stock Option

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 10,483
Date: 28 Sep 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 10,483
Exercise price: $5.28
Footnotes: F2

BBLG holding Derivative

Non-Employee Stock Option

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 4,698
Date: 28 Sep 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 4,698
Exercise price: $11.28
Footnotes: F2

BBLG holding Derivative

Non-Employee Stock Option

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 2
Date: 28 Sep 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 2
Exercise price: $11.28
Footnotes: F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

This option was granted under the Bone Biologics Corporation 2015 Equity Incentive Plan, in a transaction exempt under Rule 16b-3 and, except as otherwise provided in the award notice, vests infour equal quarterly installments.

Footnote F2

This option is fully exercisable as of the date of this report.